Shire hit by a set­back as Hunter syn­drome drug fails late-stage study

Shire’s at­tempt to de­vel­op a new for­mu­la­tion of Elaprase that could be used to pre­vent cog­ni­tive de­cline in pa­tients with rare cas­es of Hunter syn­drome has just slammed in­to a late-stage wall.

Re­searchers say the drug, SHP609, failed both the pri­ma­ry as well as key sec­ondary end­points. The pri­ma­ry fo­cused on a mea­sure of cog­ni­tion for the chil­dren in the study af­ter 12 months of treat­ment, while the key sec­ondary was an eval­u­ate of the Adap­tive Be­hav­ior Com­pos­ite for the drug and con­trol arms.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.